0%
Print report
Variant interpretation report

MLH3 c.4289_4293del, p.Arg1430LeufsTer7

NM_001040108.2:c.4289_4293del NP_001035197.1:p.(Arg1430LeufsTer7) Frameshift · exon 13 View identifiers
Classification
Uncertain significance

Variant description:

The MLH3 NM_001040108.2:c.4289_4293del (NP_001035197.1:p.(Arg1430LeufsTer7)) frameshift variant has not previously been reported in somatic cancers (COSMIC). Based on available guidelines, this variant is considered to be a Variant of Uncertain Significance (VUS).

Five-step scale from benign to pathogenic. This variant is uncertain. Select a step to read what it means.

Uncertain.The recorded classification is uncertain significance.

In plain language

Gene-level background from the recorded interpretation.

About MLH3

MLH3 is a member of the MutL-homolog family of DNA mismatch repair genes. It partners with other family members, notably MLH1, to form a complex that detects and repairs errors in DNA during replication, safeguarding genomic stability and preventing microsatellite instability, and it also helps promote meiotic crossover. Germline mutations in MLH3 are associated with hereditary nonpolyposis colorectal cancer type 7 (HNPCC7), and inactivating changes in the gene have also been found in endometrial and gastric cancers. Loss of MLH3 function increases susceptibility to tumors such as gastrointestinal cancers, indicating that it acts as a tumor suppressor.

LYFE Sciences is an AI system, and it can make mistakes. Criteria may be applied incorrectly, sources may be misread, and a confident-looking classification can still be wrong. Double-check every criterion and its underlying evidence before relying on any call.
01The reasoning

How it was classified

The recorded framework is Generic ACMG/AMP 2015 with ClinGen SVI recommendations. The criteria and strengths shown below come from the saved assessment; this page does not recalculate the classification.

Recorded applied criteria

The applied criteria and their strengths are shown as assessed under the stated framework.

Pathogenic evidence criteria: 1 Benign evidence criteria: 0
Pathogenic criteria applied · 1
PM2Moderate
PM2 · moderate

Met at Moderate: gnomAD v4.1 observes 14/1,612,958 alleles (AF 8.68e-06), below the <=0.0001 extremely-low-frequency PM2 cutoff, with zero homozygotes.

Benign criteria applied · 0

No benign criterion marked as applied in the recorded assessment.

Recorded classification: Uncertain significance

VUS: PM2 at moderate strength is the only applied criterion, and it does not satisfy a generic ACMG/AMP pathogenic or benign combination rule.

02The sources

Evidence at a glance

Evidence summaries and captured source records, where available. Missing entries should not be interpreted as negative findings.

gnomAD v4.1
gnomAD v2.1
Population frequency
14 / 1,612,958 alleles

gnomAD v4.1: 14 / 1,612,958 alleles. Recorded AF 8.67971e-06. Recorded homozygote count 0.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 3.97687e-06; MAF= 0.00040%, 1/251454 alleles, homozygotes = 0) and has highest observed frequency in the European (non-Finnish) population (AF= 8.79044e-06; MAF= 0.00088%, 1/113760 alleles, homozygotes = 0).

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

SpliceAI score
0.124 maximum delta

Recorded SpliceAI maximum delta score: 0.124. Refer to the recorded PP3/BP4 rationale for interpretation.

No listed criterion applied SpliceAI ↗
ClinVar submissions
2 reported laboratory submissions

2 Uncertain significance. ClinVar API review status: criteria provided, multiple submitters, no conflicts.

Context only ClinVar ↗
Functional evidence
Statement recorded

OncoKB identified variant-specific curated literature and context relevant to functional review; biological-effect context: Likely Loss-of-function; curated oncogenicity label: Likely Oncogenic.

No listed criterion applied OncoKB ↗
COSMIC
Cancer Hotspots
Somatic evidence
No matching record reported

This variant has not previously been reported in somatic cancers (COSMIC).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.

For specialists

Technical detail

ACMG/AMP criteria under Generic ACMG/AMP 2015 with ClinGen SVI recommendations, with the data and sources behind each one.

28 criteria with recorded statuses: 1 met · 7 not met · 10 not assessed · 10 not applicable. Open any row for the full reasoning, the rule and the evidence behind it.

Met Not met Not assessed Not applicable

No proband, parental-testing, phenotype-consistency, segregation, or non-segregation evidence sufficient to assess PS2, PM6, PP1, or BS4 is present in the available case evidence.

No VCEP covers MLH3, so generic ACMG/AMP 2015 definitions govern.

PS4 is not met because no exact-variant affected-case versus control comparison or calculable OR with 95% CI is available.

PP4 is not assessed because phenotype and family-history data are absent.

PP5 and BP6 are not met because ClinVar contains only ordinary laboratory VUS submissions and no exact-variant expert-panel pathogenic or benign classification.

BP5 is not assessed because no alternate molecular basis is documented.

Both PP3 and BP4 are not applicable because this is a frameshift variant; its SpliceAI result is not used for either criterion.

Met · 1

PM2 ModerateACMGMet at Moderate: gnomAD v4.1 observes 14/1,612,958 alleles (AF 8.68e-06), below the <=0.0001 extremely-low-frequency PM2 cutoff, with zero homozygotes. Details ▾Hide ▴
Reasoning

PM2 is met at Moderate strength. The variant is present at an extremely low frequency in the applicable control datasets: gnomAD v4.1 all-comers AF=8.67971e-06 (14/1,612,958 alleles; 0 homozygotes), with grpmax FAF=6.88e-06, and gnomAD v2.1 non-cancer exomes AF=4.22091e-06 (1/236,916 alleles; 0 homozygotes). These frequencies are below the supplied generic PM2 cutoff of <=0.0001 (0.01%). The variant is not absent, so the conclusion rests on the explicitly allowed extremely-low-frequency path. The deletion is a short indel, so the ACMG/AMP caveat about potentially poor indel calling is noted; however, the concordant observations across the large v2.1 exome and v4.1 datasets do not indicate a call artifact in this record.

Rule
PM2: Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes or Exome Aggregation Consortium. ... PM2 (moderate): <= 0.0001 — ACMG/AMP 2015 PM2 (Richards et al. 2015); 0.01% is the generic cutoff for 'extremely low frequency' (PMID:25741868)
Evidence considered
  • gnomAD v4.1 all-comers: total AF=8.67971e-06 from 14/1,612,958 alleles; grpmax FAF=6.88e-06; homozygotes=0.
  • gnomAD v2.1 non-cancer exomes: AF=4.22091e-06 from 1/236,916 alleles; homozygotes=0. This exome-only non-cancer result is consistent with the default all-comers datasets.
  • The supplied generic PM2 cutoff is <=0.0001 (0.01%); both observed frequencies are below this cutoff.
Sources

Not met · 7 · evaluated, threshold not reached

PVS1 ACMG_2015Met at moderate strength: the terminal-exon frameshift escapes NMD and removes 18 of 1454 residues (1.24%), triggering the named last-exon/NMD-escape downgrade. (PVS1 changed from met (moderate) to not_met) Details ▾Hide ▴
Reasoning

NM_001040108.2 is the MANE Select/refseq-selected MLH3 transcript, and NM_001040108.2:c.4289_4293del is a five-base frameshift in exon 13, the terminal exon, producing NP_001035197.1:p.(Arg1430LeufsTer7). MLH3 loss of function is documented as an eligible disease mechanism in the supplied gene-level evidence. Because the premature stop is in the terminal exon, the predicted transcript is expected to escape the usual exon-junction-mediated NMD pathway; the ClinGen SVI PVS1 last-exon/NMD-escape downgrade therefore applies. The predicted product ends at residue 1436 versus 1454 in the reference, removing 18 of 1454 residues (1.24%), so full very-strong PVS1 is not justified and the criterion is met at moderate strength. No evidence in the supplied case materials establishes a repeat-region or transcript-relevance exception that would negate PVS1. (Pipeline rule: PVS1 changed from met (moderate) to not_met - generic mode applies ACMG/AMP 2015 strengths (Richards et al. 2015, PMID:25741868), where PVS1 is very strong, and the evidence was rated only moderate.)

Rule
PVS1: Null variant (nonsense, frameshift, canonical +/−1 or 2 splice sites, initiation codon, single or multi-exon deletion) in a gene where loss of function (LOF) is a known mechanism of disease.
Evidence considered
  • Variant Validator and the supplied PVS1 assessment identify NM_001040108.2:c.4289_4293del as a frameshift in exon 13 with protein consequence NP_001035197.1:p.(Arg1430LeufsTer7).
  • The transcript annotation identifies exon 13 as the terminal exon: coding c.4243 through the terminal exon extends to c.*3307, and the variant lies at c.4289_4293del within that exon.
  • The predicted protein terminates at residue 1436 compared with 1454 residues in the reference, removing 18 residues (1.24%).
  • The supplied gene-level PVS1 context marks MLH3 loss of function as a supported disease mechanism and the gene gate as eligible for generic PVS1 assessment.
  • The ClinGen SVI PVS1 framework is used for the named last-exon/NMD-escape downgrade; ACMG/AMP 2015 supplies the PVS1 null-variant definition and very-strong default tier.
Sources
pvs1_gene_contextpvs1_variant_assessmentpvs1_generic_framework ↗PMID:25741868 ↗
PS4 ACMG_2015Not met: no affected-case count or case-control OR is available, and reviewed literature provides no exact-variant enrichment evidence despite gnomAD frequencies of 1/251454 and 14/1612958. Details ▾Hide ▴
Reasoning

No case-control enrichment was found for exact MLH3 c.4289_4293del (p.(Arg1430LeufsTer7)). The literature_pass.json PS4 index listed PMID:26389258 and PMID:34043773, but ai_classified_papers was empty; the available paper extract for PMID:34043773 explicitly states that it does not mention MLH3 or this exact variant and provides no variant-specific clinical or population evidence. PMID:26389258 has no abstract, full-text extract, or variant-specific evidence in the case materials. Population data show only 1/251454 alleles in gnomAD v2.1 and 14/1612958 alleles in gnomAD v4.1, but no affected-case count or matched case frequency is available, so an OR and 95% CI cannot be computed. Therefore the required significant increase in affected individuals versus controls is not demonstrated, and PS4 is not met; no PS4 numeric inequality is applicable because no OR or RR estimate is available.

Rule
The prevalence of the variant in affected individuals is significantly increased compared to the prevalence in controls. ... Note 1: Relative risk (RR) or odds ratio (OR), as obtained from case-control studies, is >5.0 and the confidence interval around the estimate of RR or OR does not include 1.0. See
Evidence considered
  • gnomAD v2.1 reports 1/251454 alleles (AF 3.97687e-06); gnomAD v4.1 reports 14/1612958 alleles (AF 8.67971e-06).
  • PMID:34043773 was checked through its extracted full-text finding: it does not mention MLH3 or c.4289_4293del and reports no variant-specific clinical, segregation, or population evidence.
  • The literature packet's PS4 candidates were PMID:26389258 and PMID:34043773; no AI-classified paper was present, and PMID:26389258 had no usable abstract, full-text extract, or exact-variant evidence available.
  • No affected-case frequency or control comparison was available, so no odds ratio or 95% confidence interval could be calculated.
Still missing
  • A case cohort with exact-variant carrier counts and an appropriate unaffected or matched-ancestry control comparison would be needed to calculate OR and 95% CI.
Sources
PP5 ACMG_2015Not met: ClinVar has two laboratory VUS submissions and zero expert-panel submissions, with no exact-variant Pathogenic or Likely pathogenic classification. Details ▾Hide ▴
Reasoning

The exact variant is present in ClinVar as Uncertain significance with two clinical-laboratory submissions and zero expert-panel submissions. No exact-variant ClinVar expert-panel classification of Pathogenic or Likely pathogenic is available. The literature packet's PP5 candidates, PMID:26389258 and PMID:34043773, do not provide a validated exact-variant pathogenic expert-panel classification; PMID:34043773's extracted full text does not mention MLH3 or the variant. Therefore the generic PP5 requirement is not satisfied.

Rule
Reputable source recently reports variant as pathogenic, but the evidence is not available to the laboratory to perform an independent evaluation.
Evidence considered
  • ClinVar variation 544283 exactly matches NM_001040108.2:c.4289_4293del and reports Uncertain significance, two clinical-laboratory submissions, and zero expert-panel submissions.
  • PMID:34043773 was reviewed from its extracted full-text finding and does not mention MLH3 or the exact variant.
  • The literature packet lists PMID:26389258 and PMID:34043773 as PP5 candidates, but no exact-variant ClinVar expert-panel pathogenic or likely pathogenic classification is documented.
Sources
BA1 ACMGNot met: gnomAD v4.1 grpmax FAF is 6.88e-06, far below the 0.05 BA1 threshold, with the qualifying NFE population contributing 1,179,980 observed alleles. Details ▾Hide ▴
Reasoning

BA1 is not met. The applicable gnomAD v4.1 all-comers record reports grpmax FAF=6.88e-06 (0.000688%), with the highest observed population point estimate 1.18646e-05 in European (non-Finnish) individuals; the 14/1,179,980 NFE alleles provide more than 2,000 observed alleles. The filtering allele frequency is far below the generic BA1 threshold of >=0.05 (5%). The Amish subgroup has only 912 alleles and therefore cannot support BA1 under the minimum population-size requirement. The non-cancer gnomAD v2.1 exome frequency is also only 4.22091e-06 (1/236,916).

Rule
BA1 (stand-alone): >= 0.05 — ACMG/AMP 2015 stand-alone benign allele frequency (PMID:25741868)
Evidence considered
  • gnomAD v4.1 all-comers: grpmax FAF=6.88e-06; total AF=8.67971e-06 from 14/1,612,958 alleles; European (non-Finnish) point estimate=1.18646e-05 from 14/1,179,980 alleles; homozygotes=0.
  • gnomAD v2.1 non-cancer exomes: AF=4.22091e-06 from 1/236,916 alleles; homozygotes=0. This is consistent with the default all-comers result, and no governing VCEP specifies a different population source.
  • The gnomAD v4.1 Amish subgroup has 0 alternate alleles among 912 alleles, below the required 2,000 observed-allele minimum for using a small isolate population to support BA1 or BS1.
Sources
BS1 ACMGNot met: gnomAD v4.1 grpmax FAF is 6.88e-06 (0.000688%), far below the generic BS1 threshold of 0.01 (1%). Details ▾Hide ▴
Reasoning

BS1 is not met. Under the generic ACMG/AMP definition, BS1 requires an allele frequency greater than expected for the disorder. The appropriate filtering frequency is gnomAD v4.1 grpmax FAF, which is 6.88e-06 (0.000688%), based on 14 alternate alleles among 1,612,958 total alleles; the highest observed population point estimate is European (non-Finnish) 1.18646e-05 from 14/1,179,980 alleles, but the point estimate is not used for this assessment. The grpmax FAF is far below the supplied generic BS1 threshold of 0.01 (1%) (Whiffin et al. 2017, PMID:28518168), and the variant has zero observed homozygotes. No VCEP-specific population source or maximum-credible-frequency calculation overrides the generic assessment, and the observed frequency does not support an allele frequency greater than expected for the disorder.

Rule
Allele frequency is greater than expected for disorder.
Evidence considered
  • gnomAD v4.1 joint data for MLH3 NM_001040108.2:c.4289_4293del: grpmax FAF=6.88e-06; total AF=8.67971e-06 from 14/1,612,958 alleles; homozygotes=0.
  • gnomAD v4.1 European (non-Finnish) point estimate is AF=1.18646e-05 from 14/1,179,980 alleles; this popmax point estimate was not used because the governing frequency instruction requires filtering grpmax FAF.
  • Generic BS1 calibration supplied for this case: >=0.01; per-gene derivation is preferred (Whiffin et al. 2017, PMID:28518168). The observed grpmax FAF is below this threshold.
  • ACMG/AMP 2015 criterion definition supplied for this case: BS1 is applied when allele frequency is greater than expected for the disorder (Richards et al. 2015, PMID:25741868).
Sources
BS2 ACMG_2015Not met: gnomAD v4.1 reports zero homozygotes for the variant, and no documented healthy-adult observation establishes BS2 for a dominant, recessive, or X-linked disorder. Details ▾Hide ▴
Reasoning

BS2 is not met. gnomAD v2.1, gnomAD v2.1 non-cancer exomes, and gnomAD v4.1 each report zero homozygotes for this frameshift, so there is no observed healthy homozygous individual to support BS2 under the recessive interpretation suggested by the available MLH3 disease context. The population records also do not provide a documented healthy-adult clinical observation of this exact variant in a dominant heterozygous or X-linked hemizygous context. A single heterozygous allele in a population database is not, by itself, the ACMG/AMP BS2 observation required for an early-onset, fully penetrant disorder.

Rule
BS2: Observed in a healthy adult individual for a recessive (homozygous), dominant (heterozygous), or X-linked (hemizygous) disorder, with full penetrance expected at an early age.
Evidence considered
  • gnomAD v4.1 all-comers: 14/1,612,958 alleles and 0 homozygotes; NFE 14/1,179,980 alleles and 0 homozygotes.
  • gnomAD v2.1 all-comers: 1/251,454 alleles and 0 homozygotes; gnomAD v2.1 non-cancer exomes: 1/236,916 alleles and 0 homozygotes.
  • No case-specific source documents this exact variant in a clinically evaluated healthy adult, and the available population records do not establish the genotype-and-phenotype observation required by BS2.
Sources
BP6 ACMG_2015Not met: ClinVar shows two laboratory VUS submissions and zero expert-panel submissions, with no exact-variant Benign or Likely benign expert-panel classification. Details ▾Hide ▴
Reasoning

The exact variant is present in ClinVar as Uncertain significance from two clinical-laboratory submissions, with zero expert-panel submissions. No exact-variant ClinVar expert-panel classification of Benign or Likely benign is available, and the reviewed literature does not supply one. Ordinary laboratory submissions, the aggregate VUS label, and non-expert assertions cannot trigger BP6 under the requested rule. Therefore BP6 is not met.

Rule
Reputable source recently reports variant as benign, but the evidence is not available to the laboratory to perform an independent evaluation.
Evidence considered
  • ClinVar variation 544283 exactly matches NM_001040108.2:c.4289_4293del and reports Uncertain significance, two clinical-laboratory submissions, and zero expert-panel submissions.
  • No exact-variant expert-panel Benign or Likely benign classification is documented; the available literature packet contains no validated benign expert-panel assertion.
Sources

Not assessed · 10 · no assessment recorded

PS2 ACMG_2015Not assessed: no documented proband phenotype, family-history assessment, or confirmed maternity and paternity is available for this variant. Details ▾Hide ▴
Reasoning

No case-level evidence establishes that the variant is de novo, confirms both maternity and paternity, documents disease in the patient, and excludes a family history. The available ClinVar record identifies the variant and its germline submissions but provides no proband or parental-testing results.

Rule
De novo (both maternity and paternity confirmed) in a patient with the disease and no family history.
Evidence considered
  • ClinVar variation 544283, exact variant NM_001040108.2(MLH3):c.4289_4293del (p.Arg1430fs): two germline clinical-testing submissions are listed, but the record contains no proband phenotype, family-history assessment, or parental genotypes/testing results.
Still missing
  • Proband disease phenotype and clinical diagnosis
  • Family-history documentation
  • Variant testing results for both biological parents
  • Explicit maternity and paternity confirmation
Sources
PS3 ACMG_2015Not assessed: the only functional study used a different truncated MLH3 construct and did not test c.4289_4293del. Details ▾Hide ▴
Reasoning

The available functional publication evaluated MLH3 biology using a mammalian two-hybrid assay and a stable microsatellite-instability assay with a dominant-negative N-terminal-deletion MLH3 construct, but it did not test NM_001040108.2:c.4289_4293del or p.(R1430Lfs*7). The study therefore provides gene-level functional context but not well-established variant-specific evidence supportive of a damaging effect for this frameshift, and PS3 cannot be assigned.

Rule
Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product.
Evidence considered
  • PMID:10615123: Mammalian two-hybrid testing examined MLH1 interaction with MLH3 constructs, and stable 293T/COS7 cell assays tested a dominant-negative N-terminal-deletion MLH3 construct that induced microsatellite instability; the case variant was not tested.
  • The available assay evidence is indirect gene-level context rather than a validated, reproducible functional result for this specific frameshift variant, so it is insufficient to meet PS3 at any ACMG/AMP 2015 strength.
Still missing
  • A validated, reproducible functional assay directly testing MLH3 c.4289_4293del or p.(R1430Lfs*7), with appropriate controls and biologically relevant readouts, is unavailable.
Sources
PM3 ACMG_2015Not assessed: no documented parental testing, phase, affected-proband observation, or pathogenic allele is available for NM_001040108.2:c.4289_4293del. Details ▾Hide ▴
Reasoning

PM3 is not assessed. The variant is a frameshift in MLH3, but the available case evidence does not document an affected proband, a second pathogenic or likely pathogenic MLH3 variant, parental testing, or phase showing this variant in trans. The available records therefore do not establish the recessive-disease context and trans configuration required to apply PM3.

Rule
PM3: For recessive disorders, detected in trans with a pathogenic variant ... Note: This requires testing of parents (or offspring) to determine phase.
Evidence considered
  • The case record identifies NM_001040108.2:c.4289_4293del as a frameshift predicted to produce NP_001035197.1:p.(Arg1430LeufsTer7), but provides no affected-proband case details, second pathogenic allele, parental testing, or phase result.
  • ClinVar variation 544283 contains two germline submissions classified as uncertain significance and no phase or parental information relevant to PM3.
Still missing
  • Confirm whether the relevant MLH3 disorder is recessive in this case.
  • Document an affected proband and a second pathogenic or likely pathogenic variant.
  • Obtain parental or offspring testing establishing the variants are in trans.
PM6 ACMG_2015Not assessed: no report documents an assumed de novo occurrence or provides the proband and parental information needed to evaluate it. Details ▾Hide ▴
Reasoning

No case-level evidence establishes an assumed de novo occurrence. The available ClinVar record does not report a proband, disease phenotype, family history, or parental testing, so PM6 cannot be applied at its 2015 strength.

Rule
Assumed de novo, but without confirmation of paternity and maternity.
Evidence considered
  • ClinVar variation 544283, exact variant NM_001040108.2(MLH3):c.4289_4293del (p.Arg1430fs): the available record provides no case-level statement of assumed de novo status and no parental or family-history data.
Still missing
  • Case report identifying the proband
  • Disease phenotype
  • Family-history assessment
  • Parental testing or an explicit statement that de novo status is assumed
Sources
PP1 ACMG_2015Not assessed: no affected relatives or informative meioses are reported to demonstrate co-segregation of the variant with disease. Details ▾Hide ▴
Reasoning

No affected family members, meioses, co-segregation observations, or gene-specific family data are reported for this variant. The available ClinVar record contains no segregation analysis, so PP1 cannot be applied at supporting strength or increased strength.

Rule
Co-segregation with disease in multiple affected family members in a gene definitively known to cause the disease. ... May be used as stronger evidence with increasing segregation data.
Evidence considered
  • ClinVar variation 544283, exact variant NM_001040108.2(MLH3):c.4289_4293del (p.Arg1430fs): no family members, segregation results, or meiosis counts are reported.
Still missing
  • Affected relatives and their clinical diagnoses
  • Variant genotypes for affected relatives
  • Unaffected relatives and their genotypes where informative
  • Number of informative meioses and segregation results
Sources
PP4 ACMG_2015Not assessed: the patient's phenotype and family history are unavailable, so disease-specific phenotype specificity cannot be judged. Details ▾Hide ▴
Reasoning

The available case materials do not provide the patient's phenotype or family history, and no disease-specific clinical presentation can be evaluated for high specificity. Because the required phenotype information is absent, PP4 cannot be assessed.

Rule
Patient’s phenotype or family history is highly specific for a disease with a single genetic etiology.
Evidence considered
  • No patient phenotype or family-history description is present in the supplied case evidence.
Still missing
  • Patient phenotype, clinical diagnosis, and relevant family history are needed to evaluate whether the presentation is highly specific for a single-gene disease.
BS3 ACMG_2015Not assessed: no assay tested c.4289_4293del and demonstrated no damaging effect on MLH3 protein function or splicing. Details ▾Hide ▴
Reasoning

No functional study in the available evidence demonstrates that MLH3 c.4289_4293del or p.(R1430Lfs*7) has no damaging effect on protein function or splicing. The available MLH3 study used a different truncated construct and reported a damaging cellular phenotype, not a benign result for this variant; therefore BS3 cannot be assessed.

Rule
Well-established in vitro or in vivo functional studies show no damaging effect on protein function or splicing.
Evidence considered
  • PMID:10615123: The reported assay used a different dominant-negative N-terminal-deletion MLH3 construct and observed microsatellite instability; it did not evaluate the case variant or provide benign functional evidence.
  • Because no variant-specific assay shows absence of a damaging effect on MLH3 protein function or splicing, BS3 is not assessed.
Still missing
  • A validated functional assay directly testing this variant and showing preserved MLH3 protein function or normal splicing is unavailable.
Sources
BS4 ACMG_2015Not assessed: no affected relatives are reported whose genotypes demonstrate that the variant fails to segregate with disease. Details ▾Hide ▴
Reasoning

No affected family members with documented absence of the variant are reported. The available ClinVar record contains no family genotypes or non-segregation observations, so lack of segregation cannot be evaluated and BS4 cannot be applied at strong strength.

Rule
Lack of segregation in affected members of a family.
Evidence considered
  • ClinVar variation 544283, exact variant NM_001040108.2(MLH3):c.4289_4293del (p.Arg1430fs): no affected-relative genotypes, pedigree, or non-segregation observation is reported.
Still missing
  • Affected relatives with confirmed disease
  • Variant genotypes for those affected relatives
  • Pedigree and inheritance context
  • Assessment of phenocopy or multiple pathogenic variants
Sources
BP2 ACMG_2015Not assessed: no documented cis or trans phase result with a pathogenic variant is available for NM_001040108.2:c.4289_4293del. Details ▾Hide ▴
Reasoning

BP2 is not assessed. The available case evidence does not document this variant in trans with a pathogenic variant in a fully penetrant dominant disorder or in cis with a pathogenic variant in any inheritance pattern. No parental, offspring, haplotype, or other phase information is available to establish either BP2 pathway.

Rule
BP2: Observed in trans with a pathogenic variant for a fully penetrant dominant gene/disorder or observed in cis with a pathogenic variant in any inheritance pattern.
Evidence considered
  • The case record provides no affected-proband genotype, pathogenic partner variant, parental or offspring testing, haplotype data, or other evidence establishing cis or trans phase for NM_001040108.2:c.4289_4293del.
  • ClinVar variation 544283 contains two germline submissions classified as uncertain significance and no cis/trans or parental information relevant to BP2.
Still missing
  • Identify any pathogenic variant observed with this variant in the same individual.
  • Obtain parental, offspring, haplotype, or equivalent testing establishing cis or trans phase.
  • If evaluating the trans dominant pathway, establish that the relevant disorder is fully penetrant and dominant.
BP5 ACMG_2015Not assessed: no case-level alternate molecular basis or alternate pathogenic diagnosis is documented for this exact variant. Details ▾Hide ▴
Reasoning

The supplied evidence does not document this exact variant in a case with an alternate molecular basis for the disease. No patient-level alternate pathogenic variant, molecular diagnosis, or comparable alternate cause is available, so BP5 cannot be assessed.

Rule
Variant found in a case with an alternate molecular basis for disease.
Evidence considered
  • No alternate pathogenic variant or other molecular basis for disease is reported in the supplied case evidence.
Still missing
  • A documented case carrying the exact variant together with a separate molecular cause of the relevant disease would be needed.
Not applicable · 10· recorded as not applicable Show reasons ▾Hide reasons ▴
PS1 N/ANot applicable: PS1 requires a missense variant, and this is a frameshift variant. Details ▾Hide ▴
Reasoning

PS1 (Richards et al. 2015, PMID:25741868) requires the same amino acid change as a previously established pathogenic variant, evaluated regardless of the underlying nucleotide change. NM_001040108.2:c.4289_4293del in MLH3 is a frameshift variant predicted to produce NP_001035197.1:p.(Arg1430LeufsTer7). As a result, no altered amino acid exists at this position to compare against any previously established pathogenic missense variant, so PS1's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PS1 for MLH3, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_missense
Evidence considered
  • Deterministic consequence classification: frameshift (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules
PM1 N/ANot applicable: PM1 requires a missense variant, and this is a frameshift variant. Details ▾Hide ▴
Reasoning

PM1 (Richards et al. 2015, PMID:25741868) applies to a missense variant located in a mutational hot spot and/or a critical, well-established functional domain without benign variation. NM_001040108.2:c.4289_4293del in MLH3 is a frameshift variant predicted to produce NP_001035197.1:p.(Arg1430LeufsTer7). As a result, no altered residue exists to evaluate for mutational hot-spot or critical-domain membership, so PM1's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PM1 for MLH3, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_missense
Evidence considered
  • Deterministic consequence classification: frameshift (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules
PM4 N/ANot applicable: PM4 requires a protein-length change, and this is a frameshift variant. Details ▾Hide ▴
Reasoning

PM4 (Richards et al. 2015, PMID:25741868) applies to protein length changes: in-frame insertions/deletions in a non-repetitive region, or stop-loss variants that extend the protein past the reference stop codon. NM_001040108.2:c.4289_4293del in MLH3 is a frameshift variant predicted to produce NP_001035197.1:p.(Arg1430LeufsTer7). As a result, no change in protein length occurs, so there is nothing for this criterion to evaluate, so PM4's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PM4 for MLH3, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_stop_loss_or_nonrepeat_indel
Evidence considered
  • Deterministic consequence classification: frameshift (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
PM5 N/ANot applicable: PM5 requires a missense variant, and this is a frameshift variant. Details ▾Hide ▴
Reasoning

PM5 (Richards et al. 2015, PMID:25741868) requires a novel missense change at an amino acid residue where a different missense change has previously been determined to be pathogenic. NM_001040108.2:c.4289_4293del in MLH3 is a frameshift variant predicted to produce NP_001035197.1:p.(Arg1430LeufsTer7). As a result, no missense change exists at this residue to compare against a different pathogenic missense change at the same position, so PM5's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PM5 for MLH3, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_missense
Evidence considered
  • Deterministic consequence classification: frameshift (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules
PP2 N/ANot applicable: PP2 requires a missense variant, and this is a frameshift variant. Details ▾Hide ▴
Reasoning

PP2 (Richards et al. 2015, PMID:25741868) applies to a missense variant in a gene with a low rate of benign missense variation, where missense variants are a common mechanism of disease. NM_001040108.2:c.4289_4293del in MLH3 is a frameshift variant predicted to produce NP_001035197.1:p.(Arg1430LeufsTer7). As a result, the gene's missense-constraint properties are irrelevant because no missense change is present to evaluate, so PP2's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PP2 for MLH3, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_missense
Evidence considered
  • Deterministic consequence classification: frameshift (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules
PP3 N/ANot applicable: the variant is a frameshift, outside PP3's missense or splice-region/intronic scope. Details ▾Hide ▴
Reasoning

Not applicable. NM_001040108.2:c.4289_4293del is a frameshift variant, predicted to produce NP_001035197.1:p.(Arg1430LeufsTer7). Under the generic rule, PP3 applies only to missense variants or to splice-region/intronic variants through the SpliceAI path, not to frameshift or other truncating/protein-length-changing variants. The available SpliceAI max delta of 0.124 is therefore not evaluated for PP3 and cannot be used to support it.

Rule
PP3: Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.). ... PP3/BP4 apply only to a missense variant, or to a splice-region/intronic variant via the SpliceAI path - never to a frameshift, nonsense, or other truncating/protein-length-changing variant.
Evidence considered
  • Variant consequence: frameshift, NM_001040108.2:c.4289_4293del; predicted protein consequence NP_001035197.1:p.(Arg1430LeufsTer7).
BP1 N/ANot applicable: BP1 requires a missense variant, and this is a frameshift variant. Details ▾Hide ▴
Reasoning

BP1 (Richards et al. 2015, PMID:25741868) applies to a missense variant in a gene for which primarily truncating variants are known to cause disease. NM_001040108.2:c.4289_4293del in MLH3 is a frameshift variant predicted to produce NP_001035197.1:p.(Arg1430LeufsTer7). As a result, the gene's truncating-variant mechanism is irrelevant because no missense change is present to evaluate, so BP1's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP1 for MLH3, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_missense
Evidence considered
  • Deterministic consequence classification: frameshift (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules
BP3 N/ANot applicable: BP3 requires an in-frame indel in a repeat region, and this is a frameshift variant. Details ▾Hide ▴
Reasoning

BP3 (Richards et al. 2015, PMID:25741868) applies to in-frame insertions/deletions located in a repetitive region without a known function. NM_001040108.2:c.4289_4293del in MLH3 is a frameshift variant predicted to produce NP_001035197.1:p.(Arg1430LeufsTer7). As a result, the variant does not alter protein length within a repeat region, so there is nothing for this criterion to evaluate, so BP3's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP3 for MLH3, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_repeat_region_indel
Evidence considered
  • Deterministic consequence classification: frameshift (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
BP4 N/ANot applicable: the variant is a frameshift, for which a no-impact splice prediction cannot support BP4. Details ▾Hide ▴
Reasoning

Not applicable. NM_001040108.2:c.4289_4293del is a frameshift variant, predicted to produce NP_001035197.1:p.(Arg1430LeufsTer7). BP4 is outside scope for frameshift variants because a no-impact splice prediction does not negate the truncating protein effect. Consequently, the available SpliceAI max delta of 0.124 is not evaluated for BP4 and cannot establish evidence of no impact on the gene product.

Rule
BP4: Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc). ... BP4 on a frameshift or nonsense variant is not_applicable: a 'no predicted splice impact' result leaves the truncating protein effect in place, so it is not evidence of no impact on the gene product - a splice prediction for such a variant matters only to PVS1 (e.g. predicted rescue).
Evidence considered
  • Variant consequence: frameshift, NM_001040108.2:c.4289_4293del; predicted protein consequence NP_001035197.1:p.(Arg1430LeufsTer7).
BP7 N/ANot applicable: BP7 requires a synonymous variant, and this is a frameshift variant. Details ▾Hide ▴
Reasoning

BP7 (Richards et al. 2015, PMID:25741868) is defined for a synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus sequence and the nucleotide is not highly conserved. NM_001040108.2:c.4289_4293del in MLH3 is a frameshift variant predicted to produce NP_001035197.1:p.(Arg1430LeufsTer7). As a result, the encoded protein sequence is altered, so the criterion's silent-variant premise does not hold regardless of any splicing prediction, so BP7's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP7 for MLH3, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_synonymous
Evidence considered
  • Deterministic consequence classification: frameshift (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules

Identifiers

Gene
MLH3
Transcript
NM_001040108.2
Coding (HGVS c.)
NM_001040108.2:c.4289_4293del
Protein (HGVS p.)
NP_001035197.1:p.(Arg1430LeufsTer7)
GRCh38
chr14:75017150 AGAGAC>A
GRCh37
chr14:75483853 AGAGAC>A
Location and type
Exon 13 · frameshift
ClinVar
544283

Gene diagram

Every interpreted variant in MLH3, mapped onto the exon structure of NM_001040108.2. Select a row to find it on the plot.

MLH3NM_001040108.2
Fetching transcript structure from UCSC…
gnomAD v4.1 14 / 1,612,958 alleles AF 8.68e-06 · 0 homozygotes · FAF 6.88e-06
gnomAD v2.1 1 / 251,454 alleles AF 3.98e-06 · 0 homozygotes
gnomAD-Canada v1.0 Allele count data not recorded

By genetic ancestry

gnomAD v4.1

AF 8.7e-06 · 14 / 1,612,958 alleles · 0 hom · FAF 6.9e-06
European (non-Finnish)14 / 1,179,980 1.2e-05
0 alternate alleles recorded in 9 other groups: Remaining individuals, Admixed American, European (Finnish), Amish, East Asian, Middle Eastern, South Asian, Ashkenazi Jewish, African/African American.

gnomAD v2.1

AF 4e-06 · 1 / 251,454 alleles · 0 hom
European (non-Finnish)1 / 113,760 8.8e-06
0 alternate alleles recorded in 7 other groups: African/African American, Admixed American, Ashkenazi Jewish, East Asian, European (Finnish), Remaining individuals, South Asian.

Statements

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 8.67971e-06; MAF= 0.00087%, 14/1612958 alleles, homozygotes = 0) and has highest observed frequency in the European (non-Finnish) population (AF= 1.18646e-05; MAF= 0.00119%, 14/1179980 alleles, homozygotes = 0); grpmax FAF= 6.88e-06.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 3.97687e-06; MAF= 0.00040%, 1/251454 alleles, homozygotes = 0) and has highest observed frequency in the European (non-Finnish) population (AF= 8.79044e-06; MAF= 0.00088%, 1/113760 alleles, homozygotes = 0).

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

SpliceAI and Pangolin

SpliceAI acceptor lossat +51 bp
0.124
SpliceAI acceptor gainat -418 bp
0.001
SpliceAI donor lossat -54 bp
0.007
SpliceAI donor gainat -142 bp
0.044
Pangolin splice lossmagnitude shown
-0.184
Pangolin splice gain
0.005

Other predictors

REVEL
Not available
BayesDel
Not available

How the predictions were used

PP3 N/ANot applicable: the variant is a frameshift, outside PP3's missense or splice-region/intronic scope. Details ▾Hide ▴
Reasoning

Not applicable. NM_001040108.2:c.4289_4293del is a frameshift variant, predicted to produce NP_001035197.1:p.(Arg1430LeufsTer7). Under the generic rule, PP3 applies only to missense variants or to splice-region/intronic variants through the SpliceAI path, not to frameshift or other truncating/protein-length-changing variants. The available SpliceAI max delta of 0.124 is therefore not evaluated for PP3 and cannot be used to support it.

Rule
PP3: Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.). ... PP3/BP4 apply only to a missense variant, or to a splice-region/intronic variant via the SpliceAI path - never to a frameshift, nonsense, or other truncating/protein-length-changing variant.
Evidence considered
  • Variant consequence: frameshift, NM_001040108.2:c.4289_4293del; predicted protein consequence NP_001035197.1:p.(Arg1430LeufsTer7).
BP4 N/ANot applicable: the variant is a frameshift, for which a no-impact splice prediction cannot support BP4. Details ▾Hide ▴
Reasoning

Not applicable. NM_001040108.2:c.4289_4293del is a frameshift variant, predicted to produce NP_001035197.1:p.(Arg1430LeufsTer7). BP4 is outside scope for frameshift variants because a no-impact splice prediction does not negate the truncating protein effect. Consequently, the available SpliceAI max delta of 0.124 is not evaluated for BP4 and cannot establish evidence of no impact on the gene product.

Rule
BP4: Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc). ... BP4 on a frameshift or nonsense variant is not_applicable: a 'no predicted splice impact' result leaves the truncating protein effect in place, so it is not evidence of no impact on the gene product - a splice prediction for such a variant matters only to PVS1 (e.g. predicted rescue).
Evidence considered
  • Variant consequence: frameshift, NM_001040108.2:c.4289_4293del; predicted protein consequence NP_001035197.1:p.(Arg1430LeufsTer7).
BP7 N/ANot applicable: BP7 requires a synonymous variant, and this is a frameshift variant. Details ▾Hide ▴
Reasoning

BP7 (Richards et al. 2015, PMID:25741868) is defined for a synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus sequence and the nucleotide is not highly conserved. NM_001040108.2:c.4289_4293del in MLH3 is a frameshift variant predicted to produce NP_001035197.1:p.(Arg1430LeufsTer7). As a result, the encoded protein sequence is altered, so the criterion's silent-variant premise does not hold regardless of any splicing prediction, so BP7's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP7 for MLH3, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_synonymous
Evidence considered
  • Deterministic consequence classification: frameshift (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules

Statement

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.12).

7 paper records listed. No publication is explicitly linked to an applied criterion in the recorded metadata. None of the listed paper records explicitly indicates that the variant is named.

Recorded publications

  • MLH3: a DNA mismatch repair gene associated with mammalian microsatellite instability.
    The paper characterizes MLH3 as a DNA mismatch-repair gene encoding an MLH1-interacting protein. In mammalian cell assays, expression of a truncated N-terminal-deletion MLH3 construct induced microsatellite instability, consistent with a functional interaction between the MLH3 C-terminal domain and the mismatch-repair complex. The paper does not test MLH3 c.4289_4293del or p.(R1430Lfs*7).
    Does not name this variant
    PMID 10615123 ↗
    Quoted passage
    When stably overexpressed in mammalian cell culture, a truncated MLH3 induced MSI. In yeast a structurally analogous Pms1p mutant similarly induces MSI (ref. 24) by sequestering Mlh1p in functionally inactive DNA mismatch repair protein complexes. These results suggest that MLH3 can interact with MLH1 in mammalian cells.

    Discussion, paragraph 4; Results, "Functional interactions between MLH3 and MLH1"

  • Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
    The ACMG/AMP paper provides the general PVS1 framework: frameshift variants can be null variants through loss of gene product, with interpretation dependent on established loss-of-function disease mechanism and variant context such as nonsense-mediated decay, alternative transcripts, and biologically relevant exons. It does not mention MLH3 c.4289_4293del specifically.
    Does not name this variant
    PMID 25741868 ↗
    Quoted passage
    Certain types of variants (e.g. nonsense, frameshift, canonical +/−1 or 2 splice sites, initiation codon, single exon or multi-exon deletion) can often be assumed to disrupt gene function by leading to complete absence of the gene product by lack of transcription or nonsense-mediated decay of an altered transcript.

    Proposed Criteria for Interpretation of Sequence Variants, PVS1 Null variants

  • Cancer Genetics Risk Assessment and Counseling (PDQ®): Health Professional Version.
    PDQ Cancer Genetics Editorial Board · 2002
    No paper-specific finding is recorded.
    PMID 26389258 ↗
  • Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations, part II.
    Hamilton CA et al. · 2021
    No paper-specific finding is recorded.
    PMID 33451724 ↗
  • European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender.
    Seppälä TT et al. · 2021
    This paper does not mention MLH3 or the exact variant c.4289_4293del (NP_001035197.1:p.(R1430Lfs*7)). It discusses Lynch syndrome as caused by inherited pathogenic variants in MLH1, MSH2, MSH6, or PMS2, but provides no variant-specific clinical, case-control, segregation, or population evidence for MLH3 c.4289_4293del.
    Does not name this variant
    PMID 34043773 ↗
    Quoted passage
    LS is caused by inherited malfunction in one of the four MMR genes named MLH1, MSH2, MSH6 and PMS2.

    General information

  • Endometrial cancer: a review and current management strategies: part I.
    SGO Clinical Practice Endometrial Cancer Working Group et al. · 2014
    No paper-specific finding is recorded.
    PMID 24905773 ↗
  • Endometrial cancer: a review and current management strategies: part II.
    SGO Clinical Practice Endometrial Cancer Working Group et al. · 2014
    No paper-specific finding is recorded.
    PMID 24929052 ↗

Screenshots represent source records captured during evidence collection. Select one to view the recorded source content.

All source links

Statements for reports

The evidence statements recorded by the interpretation pipeline. They have not been reinterpreted by the page.

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 8.67971e-06; MAF= 0.00087%, 14/1612958 alleles, homozygotes = 0) and has highest observed frequency in the European (non-Finnish) population (AF= 1.18646e-05; MAF= 0.00119%, 14/1179980 alleles, homozygotes = 0); grpmax FAF= 6.88e-06.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 3.97687e-06; MAF= 0.00040%, 1/251454 alleles, homozygotes = 0) and has highest observed frequency in the European (non-Finnish) population (AF= 8.79044e-06; MAF= 0.00088%, 1/113760 alleles, homozygotes = 0).

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

ClinVar

This variant has been reported in ClinVar as Uncertain significance (2 clinical laboratories). (ClinVarID = 544283)

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.12).

Functional

OncoKB identified variant-specific curated literature and context relevant to functional review; biological-effect context: Likely Loss-of-function; curated oncogenicity label: Likely Oncogenic.

Somatic

This variant does not lie in a statistically significant hotspot. This variant has not previously been reported in somatic cancers (COSMIC).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.